Showing posts with label infants. Show all posts
Showing posts with label infants. Show all posts

Monday, September 20, 2010

Infant/Toddler Head-Circumference Charts May Misdiagnose Patients, Children's Hospital Study Finds

/PRNewswire/ -- The most common charts used by pediatricians to measure head growth in infants and toddlers may be inaccurate, potentially leading to delayed diagnoses, unnecessary tests, and parental worry, according to new research from The Children's Hospital of Philadelphia.

The study, which appears online today in the journal Pediatrics, is the first study to evaluate the validity of these head-circumference curves in the U.S. primary care population.

Head-circumference growth curves are used by pediatricians millions of times annually to identify children who may need extra follow-up or testing because of a large head, also called macrocephaly, or a rapidly growing head. Many children with macrocephaly or a rapidly growing head are healthy, but in some children these findings signify a problem.

"The study was done because primary care doctors were concerned that the curves weren't working well for our patients," said study leader Carrie Daymont, M.D., a pediatric researcher formerly at The Children's Hospital of Philadelphia.

The researchers used the electronic health records of more than 75,000 infants in the Children's Hospital primary care network between August 2001 and January 2008. They compared the most widely used charts with actual measurements and found that the most commonly used chart would lead to a diagnosis of macrocephaly, defined as a head circumference above the 95th percentile for age, in 2.5 times more one-year-olds than expected.

The American Academy of Pediatrics recommends that all children have head-circumference measurements done at each "well child" visit until the age of two. Doctors in the U.S. plot each measurement on the growth chart from The Centers for Disease Control and Prevention (CDC). The World Health Organization (WHO) made charts in 2006 that are used in many countries.

Neither the CDC or the WHO charts worked well in the study population, the researchers said. A chart made in 1977 by the National Center for Health Statistics (NCHS) did work well in the study population, classifying 5 percent of children above the 95th percentile. The NCHS growth chart was replaced by the CDC growth chart in 2000.

When using the CDC curves, the percentage of children diagnosed with macrocephaly changes with age. One-fifth of the expected number of one-month olds and 2.5 times the expected number of one-year-olds were classified as having macrocephaly, or being above the 95th percentile. Many of these older infants above the 95th percentile may have received unnecessary follow-up tests and specialty referrals, and their parents may have been unnecessarily worried, the researchers said.

"We were noticing that we had a larger-than-expected number of children labeled as having large and rapidly growing head circumferences," Daymont said.

Using the CDC curves may cause a delay in diagnosis in babies under two months old with diseases causing large heads, and may cause children 6 months to 3 years to be labeled as having large or rapidly growing heads, when in fact they are healthy and have a typical head size, Daymont said. Use of the WHO curves would cause an excess of children to be labeled as having large heads at all ages. The researchers at Children's Hospital used the data from this study to develop a new growth curve.

"More research is also needed to determine how doctors can use head circumference growth curves to identify children with problems without causing unnecessary worry to parents of healthy children," said David Rubin, M.D. , M.S.C.E., a pediatric researcher at Children's Hospital and a senior author on the study. "We are currently working on research related to this question."

The team at Children's Hospital is currently evaluating other sources of data to see if the new head-circumference growth curves work in other populations.

Other study authors are Chris Feudtner, M.D., M.P.H., Ph.D., of Children's Hospital and Wei-Ting Hwang, Ph.D., of the Center for Clinical Epidemiology and Biostatistics at The University of Pennsylvania.

"Head-Circumference Distribution in Large Primary Care Network Differs from CDC and WHO Curves," Pediatrics, published online Sept. 20, 2010. http://www.pediatrics.org.

----
Community News You Can Use
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter:  @GAFrontPage

Friday, May 14, 2010

FDA Revises Recommendations for Rotavirus Vaccines

The U.S. Food and Drug Administration today revised its recommendations for rotavirus vaccines for the prevention of the disease in infants and has determined that it is appropriate for clinicians and health care professionals to resume the use of Rotarix and to continue the use of RotaTeq.

The agency reached its decision based on a careful evaluation of information from laboratory results from the manufacturers and the FDA’s own laboratories, a thorough review of the scientific literature, and input from scientific and public health experts, including members of the FDA’s Vaccines and Related Biological Products Advisory Committee that convened on May 7, 2010 to discuss these vaccines.

The FDA also considered the following in its decision:

* Both vaccines have strong safety records, including clinical trials involving tens of thousands of patients as well as clinical experience with millions of vaccine recipients.
* The FDA has no evidence that PCV1 or PCV2 pose a safety risk in humans, and neither is known to cause infection or illness in humans.
* The benefits of the vaccines are substantial, and include prevention of death in some parts of the world and hospitalization for severe rotavirus disease in the United States. These benefits outweigh the risk, which is theoretical.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter:  @GAFrontPage

Wednesday, September 30, 2009

Where Surgery Was the Standard, Casting May Be the Future

/PRNewswire/ -- When parents are told their babies' scoliosis needs treatment, they often try bracing first. If that fails, their child will need surgery to place metal rods in their backs with spinal fusion later on. These children face the risk of complications from the surgery and their backs and chests may be stiff for life.

New research from the University of Rochester Medical Center (URMC) (http://www.urmc.rochester.edu/) challenges that treatment convention and may lead doctors to choose to tweak an old technology - casting - over using high-tech implantable devices. Casting has fewer, and less serious, potential complications, and it requires no surgery. In fact, with the right training and equipment, the specialized, series of casts can be done as outpatient procedures.

"Best of all, we can cure some children with progressive infantile scoliosis, something we can't do with surgery and devices," said James O. Sanders, M.D., chief of Pediatric Orthopaedics at the URMC's Golisano Children's Hospital and author of the research published in this month's Journal of Pediatric Orthopedics. "If we cast these children before their curvatures become severe and before they turn 2, our chances of avoiding surgery and potentially curing them are much better."

The study followed 55 patients with progressive infantile scoliosis (or early-onset scoliosis) a rare and potentially fatal form of spinal curvature, at Shriners Hospitals for Children in Erie, Pa., Salt Lake City and Chicago. Pediatric orthopaedic specialists used a method of casting, called EDF (for extension, derotation and flexion) that capitalizes on children's rapid growth to untwist and un-curve their spines over time. The method uses a specialized table and casts with strategically placed holes. Sanders and URMC colleague Paul Rubery, M.D., an orthopaedic surgeon, are two of only a handful of surgeons nationwide who use this specialized method with the goal of curing, not just delaying surgery.

Children are given anesthesia and ventilated during the casting because the pressure on the chest during the procedure can make breathing difficult. The cast may extend over the shoulders like a tank-top and down to the pelvis, but large holes are left open between to relieve pressure on the chest and abdomen while preventing the ribs from rotating. The entire procedure can take less than an hour. Depending on the child's age and severity of the curvature, the series of casts (removed and refitted every eight to 12 weeks) could be completed in about two years.

Although the casts can be restrictive and cause some trouble with mobility, initially, Sanders said parents are almost always surprised by how quickly their children adapt and how little having a cast changes their lives. Children can't swim or be immersed in a bath, but they are otherwise unrestricted in their activities.

Current treatments, such as the vertical expandable prosthetic titanium rib (VEPTR), which are attached to the inside of the ribs and adjusted over time, and growing rods, which are inserted near the spine and lengthened over time, are aimed at delaying spinal fusion. They are not meant to be a cure for the disease, and they present a whole host of potential complications, such as infection, pulling loose and causing stiffness in the chest and back.

"Casting remains the only method which can cure some of these curves," Sanders said.

But casting doesn't cure all curvatures and some children may still require growing rods of the VEPTR. Among children in this study a little more than 10 percent saw their curves worsen and they needed surgery. Sanders said his future research will focus on finding the best treatment options for these children, for older children and for those with large curvatures.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Friday, September 4, 2009

Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive

/PRNewswire/ -- Approximately one-half of all infants are infected with the respiratory syncytial virus (RSV) during the first year of life, and almost all children have been infected at least once by the time they reach their second birthday. Researchers at West Virginia University have discovered what makes RSV such a severe and persistent illness.

Senior author Giovanni Piedimonte, M.D., and his team have discovered that RSV prompts the release of a molecule that keeps the invaded cells alive despite the infection. The mechanism allows infected cells to survive for a longer period of time while they continue to produce viral particles, thus contributing to the severity and persistence of the infection.

Research results are published in the current issue of the journal PLoS ONE.

Inflammation of the airways caused by RSV often results in wheezing, cough and respiratory distress, creating the most common respiratory infection in infancy or childhood. Each year, an estimated 125,000 infants in the United States are hospitalized with RSV, the leading cause of infant hospitalization.

"There is still no effective therapy or medical treatment for RSV infection. While often mild, it still is responsible for the deaths of hundreds of infants in the United States each year," said Dr. Piedimonte, chair of the WVU Department of Pediatrics and physician-in-chief of WVU Children's Hospital. "The virus also strikes in nursing homes and causes deaths in the elderly population, so understanding how it works is critical."

Piedimonte said up to 500 infants may die of the infection each year. RSV may also predispose children to long-term health problems such as asthma. Other groups at high risk for severe RSV disease include the elderly, adults with underlying respiratory or cardiac disease, and those with a compromised immune system.

"Viruses must find a way to survive inside the host, and in this case RSV has found a way of keeping alive the cells that they infect," Piedimonte explained. "The virus invades the cell, which then produces a small molecule called NGF, or nerve growth factor. NGF allows the cell to survive while the virus reproduces itself. Finally, the cell explodes releasing new viral particles ready to infect the neighboring cells."

In determining how the virus instructs the infected cell to prolong its life, the researchers may have established a blueprint for development of new anti-viral drugs aimed at interfering with the action of NGF, Piedimonte said. He added that RSV may prefer the lower respiratory tract specifically because the smaller airways there allow for more efficient production of NGF.

"The interesting part of the RSV infection is that the viruses induce NGF production within an hour of coming into contact with the human cells - that is, even before they start multiplying," said the paper's lead author, Sreekumar Othumpangat, Ph.D., a researcher in the WVU Pediatric Research Institute.

Children born prematurely as well as those with chronic lung or heart disease are at higher risk for severe RSV infections.

The laboratory studies were done using human cells. Now that Piedimonte's team has discovered how RSV prolongs the life of its host cell, they are proceeding with other studies to see if they can pinpoint the same mechanism in common cold and influenza viruses.

The paper's other authors are Laura F. Gibson, deputy director of the Mary Babb Randolph Cancer Center at WVU, and Lennie Samsell, a research assistant in the Pediatric Research Institute.

The article, "NGF Is an Essential Survival Factor for Bronchial Epithelial Cells during Respiratory Syncytial Virus Infection," is available online at http://dx.plos.org/10.1371/journal.pone.0006444.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Wednesday, January 7, 2009

Preterm Births Rise 36 Percent Since Early 1980s

/PRNewswire-USNewswire/ -- New government statistics confirm that the decades-long rise in the United States preterm birth rate continues, putting more infants than ever at increased risk of death and disability according to the March of Dimes.

Nearly 543,000 babies were born too soon in 2006, according to the National Center for Health Statistics, which today released "Births: Final data for 2006," National Vital Statistics Reports; Vol. 57, No. 7. The nation's preterm birth rate (birth before 37 completed weeks gestation) rose to 12.8 percent in 2006 -- that's a 36 percent increase since the early 1980s.

The report attributed much of the increase to the growing number of late preterm infants (those born at 34 to 36 weeks gestation), which increased 25 percent since 1990. The report also noted an increase in preterm births to Hispanic women, while rates were unchanged for non-Hispanic whites and blacks. However, black women continue to have the highest preterm birth rate, at 18.5 percent.

The preterm birth rate continued to rise despite the fact that multiple births, a known risk factor for preterm birth, have begun to stabilize. The rate of twin births was unchanged in 2005 and 2006, and triplets and higher order multiples declined 5 percent in 2006.

"The health consequences for babies who survive an early birth can be devastating and we know that preterm birth exacts a toll on the entire family -- emotionally and financially," said Dr. Jennifer L. Howse, president of the March of Dimes.

"We've are committed to raising public awareness about premature birth, and we believe there are concrete steps we can take to solve this problem, including ensuring that all women of childbearing age have access to health insurance and expanding our nation's investment in research into the causes and strategies to prevent preterm birth" Dr. Howse continued.

Preterm birth is the leading cause of death in the first month of life and a contributing cause in more than a third of all infant deaths. Babies who survive an early birth face the risk of serious lifelong health problems and even late preterm infants have a greater risk of breathing problems, feeding difficulties, temperature instability (hypothermia), jaundice, delayed brain development and an increased risk of cerebral palsy and mental retardation.

Last month, the March of Dimes issued its first-ever Premature Birth Report Card, which gave the United States a "D" -- and not a single "A" to any state -- by comparing 2005 preterm birth rates to the national Healthy People 2010 objective of 7.6 percent. The report card is online at www.marchofdimes.com/petition.

-----
www.fayettefrontpage.com
Fayette Front Page
Community News You Can Use
Fayetteville, Peachtree City, Tyrone
www.georgiafrontpage.com
Georgia Front Page

Tuesday, November 18, 2008

National Birth Defects Prevention Study Shows Assisted Reproductive Technology is Associated with an Increased Risk of Certain Birth Defects

Infants conceived with Assisted Reproductive Technology (ART) are two to four times more likely to have certain types of birth defects than children conceived naturally, according to a study by the CDC. The report, “Assisted Reproductive Technology and Major Structural Birth Defects, United States,” was released in the journal Human Reproduction.

“Today, more than 1 percent of infants are conceived through ART and this number may continue to increase,” says Jennita Reefhuis, Ph.D., epidemiologist at CDC′s National Center on Birth Defects and Developmental Disabilities. “While the risk is low, it is still important for parents who are considering using ART to think about all of the potential risks and benefits of this technology.”

The study shows that among pregnancies resulting in a single birth, ART (which includes all fertility treatments in which both eggs and sperm are handled, such as in vitro fertilization) was associated with twice the risk of some types of heart defects, more than twice the risk of cleft lip with or without cleft palate and over four times the risk of certain gastrointestinal defects compared with babies conceived without fertility treatments. Despite these findings, the absolute risk of any individual birth defect remains low. In the United States, cleft lip with or without palate affects approximately 1 in every 950 births; doubling the risk among infants conceived by ART would result in approximately 1 in every 425 infants being affected by cleft lip with or without palate.

The study examined multiple births separately from single births because ART increases the chance of a multiple birth. Children born as part of a multiple birth are more likely to have a birth defect regardless of use of ART. The study showed use of ART did not significantly increase the risk of birth defects among multiple births.

However, ART might contribute to the risk of major birth defects by directly increasing the risk of defects among single births. It may also have an indirect impact because ART increases the likelihood of having twins, which is a risk factor for many types of birth defects. Researchers believe this suggests the need for further studies to determine risk for ART in pregnancies with multiple births.

The study examined data from 281 births conceived with ART and 14,095 conceived without infertility treatments. The National Birth Defects Prevention Study is a population-based study that currently incorporates data from birth defects research centers in Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas and Utah. These ten centers have been working on the largest study of birth defects causes ever undertaken in the United States. Information is gathered from more than 30,000 participants to look at key questions on potential causes of birth defects. While the causes of most birth defects are unknown, studies show that smoking, alcohol, and obesity increase a mother's risk of having a child with a birth defect.

Since 1981, ART has been used in the United States to help women become pregnant. It is defined as any procedure that involves surgically removing eggs from a woman’s ovaries, combining them with sperm in the laboratory, and returning them to the woman’s body or donating them to another woman. ART does not include treatments in which only sperm are handled (i.e., intrauterine—or artificial—insemination) or procedures in which a woman takes medicine only to stimulate egg production without the intention of having eggs retrieved.

The number of infants born after ART doubled in the United States from 1996 through 2004. According to data from the 2002 National Survey of Family Growth, almost 12 percent of U.S. women aged 15-44 years have reported using infertility services. In 2005, more than 134,000 ART procedures were performed and approximately 52,000 infants were born as a result of these procedures.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Monday, November 10, 2008

Johnson & Johnson-Merck Consumer Pharmaceuticals Company Announces Urgent Voluntary Nationwide Recall of Infants' MYLICON(R) GAS RELIEF DYE FREE Drops

Johnson & Johnson-Merck Consumer Pharmaceuticals Company Announces Urgent Voluntary Nationwide Recall of Infants' MYLICON(R) GAS RELIEF DYE FREE Drops (Simethicone-Antigas) Non-Staining Due to Possible Metal Fragments

PRNewswire/ -- Johnson & Johnson-Merck Consumer Pharmaceuticals Company (JJMCP) is voluntarily recalling approximately 12,000 units of Infants' MYLICON(R) GAS RELIEF DYE FREE drops (simethicone-antigas) non-staining sold in 1 oz. plastic bottles that were distributed after October 5, 2008 nationwide. The company is taking this action in consultation with the U.S. Food and Drug Administration (FDA). Although the potential for serious medical events is low, the company is implementing this recall to the consumer level as a precaution after determining that some bottles could include metal fragments that were generated during the manufacturing process. If any medical events were to occur, most are expected to be temporary and resolve without medical treatment. Parents who have given the product to their infant and are concerned should contact their health care provider immediately.

The two lots of Infants' MYLICON(R) GAS RELIEF DYE FREE drops non-staining 1 oz. bottles included in the recall are:

Product
Code # Lot # Exp Product
71683791111-1 SMF007 09/10 Infants' Mylicon(R) Gas Relief Dye Free
Non-Staining Drops 1 oz.

71683791111-1 SMF008 09/10 Infants' Mylicon(R) Gas Relief Dye Free
Non-Staining Drops 1 oz.

Consumers can find the lot numbers on the bottom of the box containing the product and also on the lower left side of the sticker on the product bottle.

Consumers who purchased Infants' MYLICON(R) GAS RELIEF DYE FREE drops non-staining included in this recall should immediately stop using the product and contact the company at 1-800-222-9435 (Monday -- Friday, 8:00 a.m. -- 8:00 p.m. EST) or via the internet at http://www.mylicon.com/ for instructions regarding how to dispose of the product and request a replacement or refund.

Infants' MYLICON(R) drops are sold over-the counter, in retail stores and pharmacies, as an anti-gas medicine to relieve the discomfort of infant gas frequently caused by air swallowing or by certain formulas or foods.

The recall does not affect any Original Infants' MYLICON(R) GAS RELIEF products (1/2 oz. or 1 oz. size) or Infants' MYLICON(R) GAS RELIEF DYE FREE drops non-staining (1/2 oz. size).

The manufacturer has instructed retailers and wholesalers to return their inventories.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Online: www.fda.gov/medwatch/report.htm

Regular Mail: Use postage-paid FDA form 3500 available at:
http://www.fda.gov/MedWatch/getforms.htm.
Mail to MedWatch 5600 Fishers Lane, Rockville, MD
20852-9787

Fax: 1-800-FDA-0178

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Tuesday, November 4, 2008

Georgia State Study First to Confirm Long-Term Benefits of Morphine Treatment in Infants

A recent study conducted by researchers at Georgia State University is the first of its kind to demonstrate that administration of preemptive morphine prior to a painful procedure in infancy blocks the long-term negative consequences of pain in adult rodents. These studies have serious implications for the way anesthetics and analgesics are administered to neonates prior to surgery. Infant rodents that did not receive preemptive pain medication prior to surgery were less sensitive to the effects of morphine in adulthood. This means that infants undergoing invasive procedures at birth that do not receive any pain medicine will require more morphine in adulthood to modulate their pain.

This study -- conducted by Anne Z. Murphy, Ph.D., a Georgia State Professor of Neuroscience and member of the Center for Behavioral Neuroscience, and graduate student Jamie LaPrairie -- has serious clinical implications for the more than 400,000 human infants that are admitted to a newborn intensive care unit (NICU) in the United States each year.

Past studies have shown human infants born between 25-42 weeks gestation experience on average 14 painful procedures per day during the first two weeks of life with fewer than 35 percent receiving appropriate analgesic therapy.

“While such surgical procedures in preterm infants are clearly necessary, the resulting pain and inflammation has been shown to lead to negative behavioral consequences later in life,” Murphy said. “Our previous studies have shown that, just as in humans, neonatal inflammation in rodents (that did not receive preemptive pain medication) results in an increase in sensitivity to pain, stress, and decreased reaction to morphine as adults.

While evidence exists that morphine is efficacious in neonatal rodents, this is the first study to confirm the long-term behavioral benefits.

In this study, published online in Pediatric Research, a group of rat pups received an injection of morphine sulfate on the day of birth prior to inducing inflammation; another group received a saline injection instead. The groups were then raised identically and received identical procedures during a 60-day period. Rodents that received preemptive morphine behaved normally while those rats that received saline showed significant increases in pain sensitivity and were resistant to the pain relieving effects of morphine in adulthood.

“This tells us that morphine doesn’t work very well in human children and adults that were formally in the NICU and didn’t receive preemptive pain treatment, and since morphine is still the primary drug used to treat severe pain, this means that there is an entire subpopulation for which morphine doesn’t work efficiently,” Murphy said. “These results suggest that there are long-term benefits of providing all newborns with some sort of pain relieving medicine prior to the initiation of an invasive procedure.”

Murphy’s work was supported by the National Institutes of Health, the Center for Behavioral Neuroscience, and the Georgia State Brains and Behavior Program.

-----
www.fayettefrontpage.com
Fayette Front Page
Community News You Can Use
Fayetteville, Peachtree City, Tyrone
www.georgiafrontpage.com
Georgia Front Page

Wednesday, October 29, 2008

FDA Statement on Release of Bisphenol A (BPA) Subcommittee Report

We appreciate the hard work and long hours the subcommittee has invested in scientific peer review of the FDA’s draft safety assessment of the use of BPA in food contact applications. The FDA requested this peer review to provide additional insight into this complex issue. This group of distinguished scientists has devoted their considerable knowledge and experience to this effort.

The subcommittee report to the Science Board raises important questions regarding the draft safety assessment, and the FDA looks forward to the review of the subcommittee's report by the Science Board on Oct 31.

The FDA agrees that, due to the uncertainties raised in some studies relating to the potential effects of low dose exposure to bisphenol A, additional research would be valuable. The FDA is already moving forward with planned research to address the potential low dose effects of bisphenol A, and we will carefully evaluate the findings of these studies.

Consumers should know that, based on all available evidence, the present consensus among regulatory agencies in the United States, Canada, Europe, and Japan is that current levels of exposure to BPA through food packaging do not pose an immediate health risk to the general population, including infants and babies.

Regarding Canada, the FDA notes that Health Canada’s assessment of bisphenol A on newborns and infants up to 18 months of age concludes that exposure levels are below the levels that could cause health effects. Out of an abundance of caution, the Government of Canada has taken steps to restrict the use of BPA.

Parents who, as a precaution, wish to use alternatives for their bottle-fed babies can use glass and other substitutes for polycarbonate plastic bottles; avoid heating formula in polycarbonate plastic bottles; and consult their pediatrician about switching to powdered infant formula.

For a copy of the Subcommittee Report, go to:
http://www.fda.gov/oc/advisory/scienceboard/meeting103108.html.

Statement of the Acting Surgeon General, Rear Admiral Steven K. Galson, M.D., M.P.H.

"The most important thing parents can do for their babies is ensure that they receive adequate nutrition. While the best source of nutrition for babies is the mother's breast milk, infant formula remains the recommended alternative when breast milk is not an option."

-----

www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Thursday, July 17, 2008

Louise Markert’s Little Schoolhouse

When the call came in late March, Louise Markert was ready. Across campus, through the hospital and into the operating room she marched. Nestled inside the sterile plastic container she held close to her body were precious slivers of a living human organ.

Those tiny slices held the promise of life for an innocent baby sleeping just beyond the operating doors. And Markert was the only doctor in the world who could deliver the experimental therapy they represent.

It was a similar phone call 16 years ago that brought Markert to these OR doors. She had been a pediatric immunologist on call when “I got a call about a baby in Knoxville, Tenn.,” she recalls in a staccato voice rounded by remnants of her northern New York origins. “The baby had DiGeorge syndrome and they wanted to know if we could help.”

DiGeorge syndrome is a quirk of nature that occurs when something goes terribly wrong during the first trimester of an embryo’s development. It sets the stage for a complicated disease and a host of maladies, including heart defects and calcium problems. In less than 1 percent of infants affected, a severe disruption of the immune system means almost certain death.

The Knoxville doctors had turned to Duke for help because of its leaders in clinical and basic immunology, including the late Bernard Amos, Rebecca Buckley and Barton Haynes. Among Duke’s notable achievements in this area was the tissue typing that led to the success of modern-day organ transplants.

Markert, who fell in love with immunology in high school, trained at Duke under Amos. “He recommended I do pediatrics. I didn’t like kids much at that time.” But that would soon change.

Markert eventually focused her efforts on the thymus. This vital but overlooked organ is located behind the breastbone and guides the immature white blood cells from the bone marrow so they can develop into T-cells that fight off infection.

“The thymus is like a schoolhouse,” Markert says simply, offering the analogy she uses with her patients. “When you open the doors, the students — in the form of immature white blood cells — are the children who run in. Eventually they graduate to be T-cells.”

Each year, fewer than 10 infants are born with complete DiGeorge, in which they lack a thymus entirely. Without the gland, babies have little to no chance of living past their second year.

Although thymus transplants had been attempted as early as the late 1960s for other immunodeficiency diseases, there had been little success, in part because no one knew which infants could benefit.

There also were concerns about the tissue’s viability. The thymus had to be harvested from a living donor and kept alive by being sliced into tiny pieces, which allows oxygen to reach all of the tissue’s cells while it’s being tested for safety prior to implant.

Pediatric heart surgeons routinely cut through the thymus to get to the heart, and it is normally discarded during open heart surgery on very young patients. That meant there was a fairly plentiful supply of the glands, but Markert keenly remembers her mounting frustration with keeping them viable for a transplant.

“I’d slice the tissue and after a week of culture, I’d bring it to Dr. Haynes’ lab where his technicians would section it. Then I’d go over to meet with Bart Haynes (an authority on T-cells and head of Duke’s human vaccine institute) who would tell me it was dead.”

Over and over again she tried. She learned how to sustain the thymus in a lab dish of special fluid and to slice it very gently. “That’s key,” she says. “If you use too much pressure, you kill the whole thing.”

Markert distinctly remembers the day when she arrived at Haynes’ door and learned that her persistence had paid off. “It was wonderful when he finally smiled and said, ‘It’s alive.’”

“The first transplant was so stressful, you can’t imagine. The child developed a horrible rash. I thought I had given her cancer. She was a real mess.”

The 3-month wait to biopsy that thymus seemed to take forever. Finally, she and Haynes peered into the microscope. “It looked like a normal thymus. It was unbelievable.”

Although that baby lived, complete success was not yet at hand. The next three babies died. By the time the fifth child survived, Markert was recognizing some of her missteps.

“We learned a lot about how to manage the children and do better.”

She also figured out why the first child developed the rash. “I run into it all the time. The child had developed rogue T-cells. Now I use cyclosporine (an anti-rejection drug) and have no problems.”

Today, that first baby is a healthy 14-year-old. And, after 52 transplants, Markert’s procedure now boosts a 73 percent success rate. Although still considered experimental, thymus transplants are covered by some insurance companies.

Markert receives funding from the National Institutes of Health and the Food and Drug Administration to continue the research. The amount of paperwork needed to track her program and continue its funding can feel insurmountable. Stacks of papers, files and folders consume her office, yet Markert remains committed. Her staff makes her work possible, and helps her field daily referrals from around the world.

She’s had highs when patients live, and lows when she thought her entire program would be put to a penniless death. But none of it has dampened Markert’s enthusiasm for what’s become her life’s passion.

“When I started, I was told I’d never get grants and that I should work with mice. I don’t really like mice,” she says matter-of-factly.

“Now I’m helping babies live who would die otherwise. That’s what’s important to me.”

Debbe Geiger is a senior media relations specialist in the Duke Medical Center

Friday, May 30, 2008

Falls A Leading Cause Of Injury-Related Emergency Department Visits For Infants Each Year, CDC Study Shows

Half of the estimated 328,500 infants 12 months of age or younger who were treated for injuries in hospital emergency departments each year from 2001 to 2004 were injured as a result of a fall, according to a study by the Centers for Disease Control and Prevention. The first national estimate of infant injury by month of age was published in the May 2008 American Academy of Pediatrics journal, Pediatrics.

Falls were the leading cause of injury for every month during the first year of life. Because the first year of a baby’s life is a time of rapid developmental change, every month brings different injury risks as mobility develops. CDC researchers indicate that each stage of infant development, such as whether a child is crawling or walking, plays a large role in types of injuries.

"Common sense tells us, and research confirms, that injuries among infants take a significant toll," said Ileana Arias, Ph.D., director of CDC′s Injury Center. "As children develop -- in infancy and throughout childhood -- protective factors such as home safety measures and close parental supervision are critical in helping to prevent injuries."

A crucial factor is the child’s developing mobility. Stair-related injuries are an example, leading to treatment for an estimated 5,500 12-month-olds but only 800 1-month-olds.

"When parents are aware of first-year motor milestones and their associated injury risks, they can be better prepared to help predict and prevent their infants from being injured," said Julie Gilchrist, M.D., an author on the study and medical epidemiologist in CDC’s Injury Center.

The findings came from an analysis of data collected from the Consumer Product Safety Commission’s national database on injuries seen in hospital emergency departments

For more information about CDC’s prevention efforts, please link to www.cdc.gov/injury. For a copy of this study, please link to http://pediatrics.aappublications.org/.